Literature DB >> 24989115

Clinical utility of the modified Glasgow prognostic score in patients with advanced head and neck cancer.

Masahiro Nakayama1, Keiji Tabuchi1, Akira Hara1.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the prognostic potential of the modified Glasgow prognostic score (mGPS), known to reflect the degree of tumor-associated inflammation and cancer cachexia, in patients with advanced head and neck cancer.
METHODS: Patients with advanced head and neck cancer treated at the University of Tsukuba Hospital between January 2002 and December 2011 were retrospectively evaluated. They were categorized by their mGPS.
RESULTS: A total of 210 patients were enrolled in this study. Patients with an mGPS of 0 had better overall survival and disease-free survival than did those with an mGPS of 1 or 2. Multivariate analysis revealed that the mGPS was a significant risk factor for overall survival and disease-free survival.
CONCLUSIONS: Our results suggest that the mGPS is useful for predicting outcome in patients with advanced head and neck cancer and should be included in their routine clinical assessment.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer cachexia; head and neck cancer; inflammation; modified Glasgow prognostic score (mGPS); prognostic indicator

Mesh:

Substances:

Year:  2014        PMID: 24989115     DOI: 10.1002/hed.23823

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  14 in total

1.  Predictive value of salivary microRNA-320a, vascular endothelial growth factor receptor 2, CRP and IL-6 in Oral lichen planus progression.

Authors:  Minoo Shahidi; Soudeh Jafari; Mahmood Barati; Masoumeh Mahdipour; Mohammad Saeed Gholami
Journal:  Inflammopharmacology       Date:  2017-05-13       Impact factor: 4.473

2.  Editorial: Geriatrics in the 21st Century.

Authors:  B Vellas; J E Morley
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

3.  Glasgow prognostic score after concurrent chemoradiotherapy is a prognostic factor in advanced head and neck cancer.

Authors:  Pei-Hung Chang; Cheng-Hsu Wang; Eric Yen-Chao Chen; Shih-Wei Yang; Wen-Chi Chou; Jason Chia-Hsun Hsieh; Feng-Che Kuan; Kun-Yun Yeh
Journal:  Chin J Cancer Res       Date:  2017-06       Impact factor: 5.087

4.  A Simple Scoring System Predicting the Survival Time of Patients with Bone Metastases after RT.

Authors:  Wen-Yi Zhang; Hui-Fang Li; Meng Su; Rui-Fang Lin; Xing-Xing Chen; Ping Zhang; Chang-Lin Zou
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

5.  Reduced volume SIB-IMRT/IGRT to head and neck cancer in elderly and frail patients: outcome and toxicity.

Authors:  Christoph Straube; Steffi U Pigorsch; Hagen Scherb; Jan J Wilkens; Henning Bier; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2016-10-06       Impact factor: 3.481

6.  Transaminase Activity Predicts Survival in Patients with Head and Neck Cancer.

Authors:  Yukinori Takenaka; Norihiko Takemoto; Toshimichi Yasui; Yoshifumi Yamamoto; Atsuhiko Uno; Haruka Miyabe; Naoki Ashida; Kotaro Shimizu; Susumu Nakahara; Atshushi Hanamoto; Takahito Fukusumi; Takahiro Michiba; Hironori Cho; Masashi Yamamoto; Hidenori Inohara
Journal:  PLoS One       Date:  2016-10-12       Impact factor: 3.240

7.  Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.

Authors:  Teresa Magnes; Thomas Melchardt; Lukas Weiss; Christof Mittermair; Daniel Neureiter; Eckhard Klieser; Simon Gampenrieder; Gerhard Moser; Alexander Gaggl; Richard Greil; Alexander Egle
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

8.  Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan.

Authors:  Daisuke Kawakita; Yuichiro Tada; Yorihisa Imanishi; Shintaro Beppu; Kiyoaki Tsukahara; Satoshi Kano; Hiroyuki Ozawa; Kenji Okami; Yuichiro Sato; Akira Shimizu; Yukiko Sato; Chihiro Fushimi; Soichiro Takase; Takuro Okada; Hiroki Sato; Kuninori Otsuka; Yoshihiro Watanabe; Akihiro Sakai; Koji Ebisumoto; Takafumi Togashi; Yushi Ueki; Hisayuki Ota; Tomotaka Shimura; Toyoyuki Hanazawa; Shingo Murakami; Toshitaka Nagao
Journal:  Oncotarget       Date:  2017-01-03

9.  The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer.

Authors:  Nobuhiro Hanai; Michi Sawabe; Takahiro Kimura; Hidenori Suzuki; Taijiro Ozawa; Hitoshi Hirakawa; Yujiro Fukuda; Yasuhisa Hasegawa
Journal:  Oncotarget       Date:  2018-12-11

10.  Prognostic Value of the Lymphocyte-to-Monocyte Ratio in Patients with Parotid Gland Carcinoma.

Authors:  Takuya Mikoshiba; Hiroyuki Ozawa; Yoshihiro Watanabe; Mariko Sekimizu; Shin Saito; Keisuke Yoshihama; Shintaro Nakamura; Yorihisa Imanishi; Kaori Kameyama; Kaoru Ogawa
Journal:  Laryngoscope       Date:  2020-07-16       Impact factor: 3.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.